(NASDAQ: DYAI) Dyadic International's forecast annual revenue growth rate of 102.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.09%.
Dyadic International's revenue in 2026 is $3,342,195.On average, 5 Wall Street analysts forecast DYAI's revenue for 2026 to be $273,326,438, with the lowest DYAI revenue forecast at $195,052,231, and the highest DYAI revenue forecast at $353,699,538. On average, 5 Wall Street analysts forecast DYAI's revenue for 2027 to be $258,380,878, with the lowest DYAI revenue forecast at $248,248,294, and the highest DYAI revenue forecast at $265,980,315.
In 2028, DYAI is forecast to generate $1,189,854,798 in revenue, with the lowest revenue forecast at $697,519,806 and the highest revenue forecast at $1,702,418,769.